Skip to content

Mainz Intracoronary Database. The Coronary Slow-flow and Microvascular Diseases Registry

Mainzer IntraCoronAry daTabase (MICAT). Das Coronary Slow Flow- Syndrom Und Koronare Mikrozirkulationsstörungen- Register.

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02180178
Acronym
MICAT
Enrollment
1000
Registered
2014-07-02
Start date
2013-09-30
Completion date
2028-09-30
Last updated
2024-10-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Disease, Microvascular Dysfunction

Keywords

microvascular disease, coronary artery disease, Coronary artery disease, with or without microvascular dysfuntion

Brief summary

Primary goal of the registry is to collect prospective data on patients undergoing coronary angiography in Mainz. Following amendment of the procol, this study will also include patients who received an Aborb bioresorbable scaffold for the therapy of de novo stenoses.

Detailed description

Patients included in the registry will be contacted by telephone at 3,6,9, 12 months and 2, 5, 10 years after the procedure. In case coronary slow flow is shown at the index procedure, 39ml of blood will be drawn for further studies. According to the regulations of the Province Rheinland-Pfalz, national law, and with the approval of the Ethic commission of the Landesärztekammer Rheinland Pfalz, patients (n=1000) will also be retrospectively entered in the database in an anonymous way. For these patients, no specific study procedure is foreseen and the MICAT database will be only used as a platform (database of anonymous data collected during routine clinical practice).

Interventions

Sponsors

Johannes Gutenberg University Mainz
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* clinical indication to coronary angiography

Exclusion criteria

* none

Design outcomes

Primary

MeasureTime frameDescription
Major adverse cardiovascular eventsbaseline to 10 yearsIncidence of major adverse events (death, death of cardiac cause, TLR - target lesion revascularization, MI)

Secondary

MeasureTime frameDescription
Individual endpointsbaseline to 10 yearsEach individual endpoint of the MACE previously described
Other cardiovascular endpointsbaseline to 10 yearsTVR - target vessel revascularization, re-hospitalization, change in medications.

Countries

Germany

Contacts

Primary ContactTommaso Gori, PhD, Dott medicina e Chirurgia
tommaso.gori@unimedizin-mainz.de+49 6131 172829

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 14, 2026